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Cystic fibrosis (CF) lung disease is an inherited condition with an incidence rate of approximately 1 in 2500 new born babies.
CF is characterized as chronic infection of the lung which leads to inflammation of the airway. Sputum from CF patients contains
elevated levels of neutrophils and subsequently elevated levels of neutrophil serine proteases. In a healthy individual these proteases
aid in the phagocytic process by degrading microbial peptides and are kept in homeostatic balance by cognate antiproteases.
Due to the heavy neutrophil burden associated with CF the high concentration of neutrophil derived proteases overwhelms
cognate antiproteases.The general effects of this protease/antiprotease imbalance are impairedmucus clearance, increased and self-
perpetuating inflammation, and impaired immune responses and tissue. To restore this balance antiproteases have been suggested
as potential therapeutics or therapeutic targets. As such a number of both endogenous and synthetic antiproteases have been trialed
with mixed success as therapeutics for CF lung disease.
1. Introduction to Cystic Fibrosis
Cystic fibrosis (CF) is an autosomal recessive genetic disorder
caused by loss of expression or functional mutations to the
cystic fibrosis transmembrane conductance regulator (CFTR)
[1, 2]. CF affects multiple organs; however the majority of the
pathology related to CF is due to its effect on the respira-
tory system. Nonfunctional CFTR channels in CF patients
prevent the regulation of chloride and sodium ions across
epithelial membranes leading to increased and dehydrated
mucus secretions in the lungs [1]. CF patients have an
impaired ability to clear this mucus due to damage caused
to the cilia structures in the lungs and as such are therefore
highly susceptible to chronic bacterial infections within the
lung which are effectually impossible to eradicate [3]. The
ramification of chronic bacterial infection is a sustained and
detrimental inflammatory response from the body’s innate
immune system [4, 5].There are many factors which mediate
the inflammatory response to chronic bacterial infection in
CF; these include proinflammatory cytokines such as IL-1𝛽,
IL-6, IL-8, GM-CSF, and TNF-𝛼 [6, 7].
One of the key immune cell mediators of this detrimental
inflammatory response seen inCF patients is polymorphonu-
clear neutrophils [8]. In CF lungs, neutrophils represent ∼
70% of the inflammatory cell population in contrast to∼1% in
epithelial lining fluid from healthy lungs [9]. Neutrophils are
recruited to these sites of infection by increased expression of
chemoattractants such as IL-8 by lung epithelial tissue [10].
Once recruited, neutrophils are activated and release a wide
variety of molecules, such as proteases, DNA, and reactive
oxygen species in an attempt to combat bacterial infection,
further driving the inflammatory response and causing pro-
gressive tissue damage [8]. Evidence to date supports the
hypothesis that CF neutrophils may be inherently defective
[8, 11–13]. In addition to the release of proinflammatory
mediators, neutrophils in the CF lung are not successfully
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Figure 1: In the cystic fibrosis lung, antiprotease production by both innate immune cells and respiratory epithelial cells is overwhelmed by
protease production resulting mainly from neutrophils. This leads to a disruption of the homeostatic protease/antiprotease balance resulting
in a number of detrimental effects causing increase lung pathology.
cleared via macrophage phagocytosis [5, 14]. Neutrophil
necrosis further increases the levels of proinflammatory
mediators, increasing tissue damage and also increasing
the viscosity of the CF patients sputum [14]. In healthy
individuals tissue damage as a result of inflammation is in
part controlled by homeostatic regulation of proteases via
antiprotease activity. Inflammation observed in CF patients
mainly as a result of neutrophil activity is highly disruptive
to this protease/antiprotease balance as illustrated in Figure 1.
The role that these serine proteases and their inhibitors
play in the CF lung in either protecting the lung tissue or
contributing to pathology will be the subject of this review.
2. Neutrophil Serine Protease Activity in CF
Proteases degrade proteins into either polypeptides or amino
acids and are grouped on the basis of their catalytic residues.
The 4 groups of proteases are serine proteases, cysteine pro-
teases, metalloproteases, and the less common aspartic acid
proteases [15, 16]. Neutrophil serine proteases are the main
proteases implicated in the damage observed in the lungs of
CF patients; these are neutrophil elastase (NE), proteinase 3
(PR3), and cathepsin G (Cat G) [17]. All three are members
of the chymotrypsin family, and are expressed by neutrophils
[17]. Upon translation these proteases appear as inactive
precursor peptides referred to as zymogens. All three serine
proteases undergo a two-stage posttranslational modification
process in order to produce their active mature forms. The
initial stage is the cleavage of an N-terminal signal peptide
by a signal peptidase. The second stage is the cleavage of a
prodipeptide from the N-terminal by the cysteine protease
cathepsin C, which is required for enzymatic activity, and the
cleavage of a C-terminal propeptide which may be required
for packaging of the mature protein [18–22].
The mature forms of NE, PR3, and Cat G are stored in
azurophilic granules within the cytoplasm of neutrophils.
The activities of all three of these proteases are reliant on an
amino acid triad composed of aspartate, histidine, and serine
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residues [18]. These residues are interspersed at different
positions in the primary structure of each of the three serine
proteases; however these residues are brought together in an
active site region in the tertiary structure [15]. Serine pro-
teases act either intracellularly, degrading microbial proteins
in the phagosome, or extracellularly, regulating the immune
system and aiding the degradation of extracellular matrix
(ECM) components [18]. Owing to their broad range activity,
the lack of regulation of these proteases in the CF lung is
highly detrimental. The majority of research into the role of
neutrophil serine proteases in the lung has focused on NE;
however PR3 and Cat G are found at high concentrations in
the sputum and bronchial alveolar lavage fluid (BALF) of CF
patients so they therefore should not be discounted [23, 24].
2.1. Neutrophil Elastase. NE is a 29 kDa serine protease
expressed by neutrophils from the gene ELANE, located on
chromosome 19 [25]. NE is secreted upon neutrophil acti-
vation, into the phagosome during phagocytosis or released
during neutrophil necrosis. Due to the heavy neutrophil
burden associated with CF discussed previously, the lev-
els of NE in the CF airway have been shown to reach
micromolar concentrations [26]. Increased levels of NE in
the CF lung have been attributed to elevated neutrophil
numbers; however, defective neutrophil degranulation may
also play a role [27, 28]. CF neutrophils were shown to release
greater levels of elastase than non-CF controls despite the
fact that the total complement of NE in the CF neutrophil
was similar between groups [28]. This increased release may
be attributable in part to the inflammatory milieu in the CF
lung or as a result of CFTR mutation and/or dysfunction in
the cell [27–29]. Further work is needed to fully understand
the mechanisms of elevated NE activity in CF. In a healthy
individual NE functions to cleave microbial peptides liber-
ated during phagocytosis [30]. However in CF, the elevated
level of NE overwhelms the host’s cognate regulation of this
protease and as such has profound detrimental effects. The
general effect of increased NE levels in the CF lung can be
grouped into the following categories: impaired mucociliary
clearance, airway remodeling, proinflammatory activity, and
the impairing of both the innate and adaptive immune
system. The impairment of mucociliary clearance mainly
revolves around the interactions between NE and mucins.
Mucins are a family of highly glycosylated proteins produced
by epithelial cells and are the main components of the
mucus found clogging the airways of CF patients [31, 32].
NE has been shown to regulate the mucins MUC5AC and
MUC2 via activation of TNF𝛼-converting enzyme which
upregulates the expression of these mucins via the epidermal
growth factor receptor (EGFR) pathway [33–35]. The mucins
MUC4 and MUC1 are also upregulated by NE; however
their function in the lung is less understood [36–38]. NE
has also been shown to cause the hypersecretion of both
MUC5AC and MUC5B via the activation of protein kinase
pathways further increasing mucus production and its secre-
tion into the CF airway [39, 40]. Finally NE has the ability
to reduce ciliary beat frequency and degrade cilia structures.
The combined effect of reducing ciliary beat frequency and
degradation of cilia prevents mucus from being removed
from the airways therefore increasing mucus plugging in CF
patients, providing potential colonization sites for bacteria
[41–43].
When at high concentrations as found in the CF lung, NE
causes airway remodeling owing to the degradation of ECM
proteins in the airway such as elastin and fibronectin [44].
The disruption of cell surface structures by NE aggravates
neutrophil mediated inflammation increasing expression of
the proinflammatory cytokine IL-8 by airway epithelial tissue
[28, 45–47]. This increase in IL-8 may be mediated via NE
activation of the TLR-4 or EGFR cell signaling pathways, or
through the TLR-2 pathway due to the cleavage of CXCR1
receptors from neutrophil cell surfaces [46, 48, 49]. NE
release from neutrophils in the lung induces IL-8 expression
leading to further neutrophil recruitment resulting in a self-
perpetuating and detrimental cycle of neutrophil mediated
inflammation. In addition to having proinflammatory activ-
ity via acting upon IL-8 levels, NE has also been shown to
directly upregulate the proinflammatory matrix metallopro-
teases (MMPs): MMP-9 andMMP-4 [50]. Indirect activation
of MMP-9 can also be mediated by NE due to its ability to
inactivate the cognate inhibitor of MMP-9: TIMP-1 [51].
Excess NE levels in the CF lung may negatively affect
both the innate and adaptive immune systems. NE both
cleaves and downregulates flagella, an important bacterial
pathogen-associated molecular pattern (PAMP) [52, 53].
Flagella cleavage has the effect of reducing the innate immune
system’s ability to detect pathogens such as Pseudomonas
aeruginosa via TLR signaling pathways [54]. Detection and
clearance of pathogens is also inhibited by excess NE due to
cleavage of opsonizing peptides C3bi, CR1, and C5 receptor
site, rendering reduced phagocytic ability [55, 56]. NE has
also been shown to degrade antimicrobial peptides such
as lactoferrin and 𝛽-defensins directly inhibiting bacterial
killing [57, 58]. Finally NE has been shown to reduce the
ability of macrophages to clear apoptotic cells due to its
ability to cleave macrophage apoptotic cell receptors such as
CD36 [59]. In addition to inhibition of the innate immune
system, NE inhibits the adaptive immune system as research
has shown that NE cleaves T cell receptors CD2, CD4, CD8,
and CD14, impairing monocyte activation and also blocking
dendritic cell maturation and antigen presentation [60, 61].
The combined detrimental effects of excess NE in the CF
lung may result in increased bacterial survival rates heavily
contributing to the state of chronic infection associated with
CF.
NE can be found associated with the DNA structures
secreted from activated neutrophils called neutrophil extra-
cellular traps (NETs). NETs are known to be produced as
a result of reactive oxygen species; however downstream of
this, NE has been shown to regulate the formation of NETs,
with studies showing thatNE knockoutmice have an inability
to form NETs in a Klebsiella pneumonia infection model
[62, 63]. The translocation of NE to the nucleus upon neu-
trophil activation and its subsequent degradation of specific
histones promotes chromatin decondensation; this process
has been shown to be further driven by another enzyme
associated with neutrophil granulocytes: myeloperoxidase
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[63, 64]. The role of NE directly associated with NETs in the
CF lung is however poorly understood and currently under
investigation. Due to the high neutrophil burden present in
the CF lung these NET structures account for a significant
proportion of the DNA content found in mucus [65]. The
presence of this extracellular DNA in mucus increases its
plasticity increasingmucus plugging [66]. NE associatedwith
the NET structures has been shown to be less active when it
is associated with DNA; however it is also significantly less
susceptible to the actions of cognate and therapeutic protease
inhibitors [67]. It is therefore speculated that NET associated
NE could act as a reservoir for NE in the CF lung [67].
DNase treatment of sputum has been shown to significantly
increase the activity of NET associated NE but also render
it susceptible to inhibition to cognate protease inhibitors.
A combination of DNase treatment and protease inhibitor
may be a potential therapeutic treatment to alleviate the
detrimental inflammatory burden of NE in CF patients [67,
68]. Due to the wide variety of detrimental effects associated
with high levels of NE found in CF patients, NE is regarded
as the main protease responsible for inflammatory tissue
damage in the CF lung.
2.2. Proteinase 3. PR3 is a 29 kDa, 222-amino acid ser-
ine protease expressed from the PRTN3 gene by acti-
vated neutrophils [69, 70]. The biological role of PR3 in
degrading microbial peptides is similar to that of NE;
however, PR3 has been shown to degrade IL-8 resulting
in a truncated form of the chemokine with more potent
neutrophil chemoattraction activity [71]. This increase in
chemoattraction has the potential to further potentiate the
detrimental cycle of inflammation previously described for
NE. PR3 has also been shown to increase the interaction
between neutrophils and the IL-8 receptor CXCR1 [71].
The increases in both neutrophil recruitment and recep-
tor interaction with IL-8 caused by PR3 have clear detri-
mental implications for the cycle of neutrophil derived
inflammation which results in tissue damage within the CF
lung.
2.3. Cathepsin G. The remaining serine protease produced
by neutrophils implicated in CF lung disease is Cat G.
Although Cat G is a serine protease, it belongs to a larger
family of proteases which encompass the cysteine cathepsins
B, C, H, L, S, K, O, F, X, V, and W and aspartic acid
proteases (cathepsins D and E) [72]. Mature Cat G is
28.5 kDa in size and composed of 235 amino acid residues
[73]. Cat G is released upon neutrophil activation and
possesses the ability to degrade structural components of
the extracellular matrix when at high concentrations [17].
Cat G will inhibit the actions of macrophages in clearing
apoptotic cells from CF airways; this leads to a rise in
neutrophil necrosis and therefore the uncontrolled release
of proteases into the lung [17]. Finally Cat G in CF BALF
has been shown to have the highest potency of all three
neutrophil serine proteases to degrade surfactant protein A,
a peptide that facilities microbial clearance by macrophages,
the result of which is a reduction in macrophage phago-
cytic activity, and therefore increased bacterial survival
[74].
3. Antiprotease Activity in CF
In a healthy lung, antiproteases maintain a homeostatic bal-
ance with proteases, preventing the associated inflammatory
damage which results from excess protease activity. In the CF
lung it is the inability of these antiproteases to regulate their
cognate proteases that is in part responsible for the pathology
associated with infection and inflammation. A number of
antiproteases associated with CF are discussed below.
3.1. Introduction to the WFDC Protein Family. The whey
acidic protein (WAP) four disulphide core (WFDC) proteins
are a family of putativemultifunctional host defense proteins.
These proteins possess a WAP domain composed of approxi-
mately 50 amino acid residues with eight conserved cysteine
residues which form four disulphide linkages [75]. To date
there have been 18WFDCproteins identified and, in humans,
the majority of these proteins are transcribed from genes
located on chromosome 20. However two WFDC proteins
have been found to be transcribed fromgenes of chromosome
17 [76, 77]. The best characterized members of this family are
secretory leukocyte protease inhibitor (SLPI) and elafin, both
heavily implicated in the protease/antiprotease balance in the
lung.
3.2. SLPI. SLPI is an 11.7 kDa cationic serine protease
inhibitorwhich forms a constituent part of the body’s antipro-
tease screen [78]. Following posttranslational processing, the
mature SLPI peptide consists of 107 amino acid residues
and possesses two WFDC domains, each of which has four
disulphide linkages [75]. SLPI has been detected in a variety
of patient samples and is produced by a number of cell types
including neutrophils, macrophages, serous cells of bronchial
submucosal glands and nonciliated bronchial epithelial cells
[79–81]. SLPI is expressed in response to various stimuli
such as bacterial lipopolysaccharides, NE, and a number of
cytokines [80–84]. SLPI exerts antiprotease activity against
NE, cat G, trypsin and chymotrypsin, mediated via its C-
terminal WFDC domain [85]. The key active site amino acid
residue in SLPI is Leu72 since point mutation of this residue
abolishes the antiprotease activity of SLPI [85].
In addition to protease inhibition SLPI has also been
shown to inhibit inflammatory responses via a number
of differing mechanisms, both extracellularly and intracel-
lularly. SLPI acts extracellularly directly binding bacterial
lipopolysaccharide (LPS) and lipoteichoic acid (LTA), pre-
venting TLR activation [86]. SLPI acts intracellularly by
preventing the LPS/LTA induced activation of NF-𝜅B, com-
peting with p65 for binding to NF-𝜅B sites in the promoter
regions of pro-inflammatory genes such as IL-8 and TNF𝛼
therefore preventing the expression of these proinflamma-
tory cytokines and inhibiting the degradation of I𝜅B𝛼 and
IRAK which in turn prevents NF-𝜅B activation [86–88]. The
antiprotease and anti-inflammatory functions of SLPI can
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however be disrupted due to cleavage by excess concentration
of its cognate substrates. SLPI cleavage by the cysteine
proteases cathepsins B, L, and S between residues Thr67 and
Tyr68 disrupts the active site of SLPI abolishing its ability
to inhibit NE [89]. Further work demonstrated that SLPI
levels are reduced inCF patients infected by the opportunistic
pathogen P. aeruginosa [90]. Western blot analysis of BALF
from these patients showed SLPI to be cleaved, an observation
not seen in CF patients who were negative for P. aeruginosa
[90]. Further investigation identified this cleavage of SLPI to
be caused by excessive levels of NE present as a result of P.
aeruginosa infection [90]. NE-cleaved SLPI loses the ability
to bind LPS andNF-𝜅B consensus oligonucleotides [90]. NE-
cleaved SLPI however maintains some antiprotease activity
as this activity is mediated by the C-terminal domain which
remains intact after cleavage [90]. The proteolytic cleavage of
SLPI by NE could have implications for its use as an anti-
inflammatory therapeutic in CF patients.
3.3. Elafin. Elafin, like SLPI, has been shown to be expressed
inmacrophages and neutrophils [77].Mature elafin is formed
from the cleavage of a 12 kDa, 117-amino acid long precursor
peptide called preelafin or trappin-2 by tryptase [91, 92].
The mature elafin peptide has a relative mass of 6 kDa and
possesses 57 amino acid residues [91, 93]. Elafin has two
conserved domains, a cementoin domain which acts as a
substrate for the enzyme transglutaminase, mediating the
incorporation of elafin into extracellular matrix proteins, and
the characteristic WFDC domain [76, 94]. The high level
of homology seen in the WFDC domain between SLPI and
elafin would suggest that like SLPI, elafin functions as a
protease inhibitor.This was shown to be the case as elafin, like
SLPI, possesses antiprotease activity against NE, trypsin, and
chymotrypsin [93, 95]. However, unlike SLPI elafin possesses
antiprotease activity against PR3 but not against Cat G [93].
In addition to antiprotease activity, elafin also possesses
anti-inflammatory activity, and similar to SLPI, functions
in both an intracellular and extracellular manner. Elafin
has been shown to inhibit NF-𝜅B activation in monocytes
stimulated by LPS and LTA therefore causing a reduction
in inflammatory cytokine expression [96]. Elafin was also
shown to inhibit proteosome pathways evidenced by the
buildup of ubiquitinated IRAK-1 and I𝜅B𝛼 in LPS-stimulated
monocytic cells [96]. Elafin, like SLPI, will also neutralize
LPS. In vivo recombinant trappin-2 has been shown to reduce
proinflammatory cytokines MIP-2, KC (murine IL-8 homo-
logue), and TNF-𝛼 in LPS-treated mice [97]. Neutrophil
influx into the lung and protease activity was also seen to
be reduced in mice treated with recombinant trappin-2 and
stimulated with LPS [97, 98]. Elafin has been proposed as
a therapeutic in the treatment of pulmonary arterial hyper-
tension with Proteo Biotec Inc. carrying out phase I clinical
trials of elafin with measured success. Elafin treatment for
pulmonary arterial hypertension is currently in phase II
trials. If the trialling of elafin to treat pulmonary arterial
hypertension is successful, it could be used as a potential
treatment in CF. Experimental evidence has however shown
that like SLPI, elafin is proteolytically cleaved by excess NE
in the BAL fluid of CF patient infected with P. aeruginosa
[99, 100]. The effects of this cleavage were the inactivation
of elafin’s anti-neutrophil elastase activity due to cleavage
of the protease-binding loop. Interestingly the antibacterial
properties of elafin were not affected by cleavage [100].
Proteolytic cleavage of elafin may have implications for its
efficacywhen being used as a therapeutic in vivo. Recent work
has shown that mutating key residues at the NE cleavage site
in elafin results in a peptide with similar antiprotease activity
as thewild-type formbutwith significantly increased stability
and anti-inflammatory activity [101]. When compared to
wild-type, the mutant forms of elafin were shown to have
improved LPS neutralizing activity in vitro and increased
anti-inflammatory activity when employed in an acutemodel
of pulmonary inflammation induced by P. aeruginosa LPS
[101].
In addition to their antiprotease and anti-inflammatory
function both SLPI and elafin have been shown to possess
antimicrobial activity against both Gram negative and Gram
positive organisms [102]. Both SLPI and elafin are cationic
peptides and this property may mediate their antibacterial
activity. Bacterial species reported to be susceptible to SLPI
and elafin include P. aeruginosa and Staphylococcus aureus
both of which are heavily implicated in the colonization
of adult and juvenile CF patients, respectively [102, 103].
Although SLPI’s antibacterial activity is mainly mediated
by the N-terminus of the peptide, antibacterial activity was
observed to be maximal when the peptide was complete
with mutation of the C-terminal WFDC domain shown to
result in a slight reduction in antibacterial function [102].The
antibacterial activity of elafin is mediated by both theWFDC
domain and the cementoin domain [104]. Interestingly the
precursor peptide to elafin, trappin-2, has been shown to
possess greater antibacterial activity than the mature peptide
[103].
3.4. Alpha-1 Antitrypsin. Alpha-1 antitrypsin (AAT) is a
serine protease inhibitor shown to be active against trypsin,
plasmin, Cat G, MMP-12 in addition to NE [105–108]. AAT
is expressed as a 418-amino acid protein which undergoes
posttranslational cleavage of a 24-amino acid signal pep-
tide and glycosylation to form a 52 kDa mature peptide
[109]. Expression of AAT mainly takes place in hepatocytes;
however, AAT expression has been observed in respiratory
epithelial cells, macrophages, and neutrophils [109, 110].
Aerosolized AAT therapy has been proposed as a treatment
for the inflammatory damage caused by neutrophil serine
proteases in CF patients for a number of years. However
a trial conducted with aerosolized AAT showed only a
tending relationship toward reduced NE in patients treated
with AAT after 4 weeks and did not identify any anti-
inflammatory effects of AAT treatment [111]; this trial did
however show significant reductions in NE/AAT complexes
and myeloperoxidase in the AAT treated cohort [111]. Fur-
thermore, CF patients receiving aerosolized AAT did not
exhibit significant reductions in Pseudomonas counts in
comparison to the placebo group [111]. The results of the
Martin et al. [111] study were however contradicted by a
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second clinical trial published one year later which showed
AAT to have significant anti-inflammatory effects [112]. This
trial involved the aerosolized delivery of AAT to CF patients
and found a significant reduction in NE, IL-8, IL-1𝛽, and
TNF-𝛼 levels after 4 weeks of treatment in comparison to
baseline; however no increase in FEV1 was observed [112].
In addition, AAT treatment reduced neutrophil counts and
there was a reduction in P. aeruginosa CFUs [112]. The ability
of AAT to regulate its cognate proteases in the CF lung may
however be curtailed by high reactive oxygen species levels as
a result of increased neutrophil burden [112, 113]. Oxidation of
residue Met358 in the active site of AAT renders the protease
inactive [47]. AAT can also be cleaved and inactivated by
MMPs [114, 115]. If MMP cleavage of AAT takes place in the
CF lung the effects could potentially be decreased inhibition
of neutrophil serine proteases and therefore continuing the
detrimental effects of these peptides. Martin et al. [111] and
Griese et al. [112] are the two most recent clinical trials using
ATT in CF patients; however there are a number of NIH
funded trials currently in progress in the US investigating the
use ofATT inCF treatment [111, 112].The results of these trials
may provide further clarification on the efficacy of using this
antiprotease as a CF therapeutic.
3.5. Synthetic Serine Protease Inhibitors. In addition to the
endogenous protease inhibitors such as SLPI and elafin being
trialled for use as anti-inflammatory therapeutics in CF, a
number of synthetic inhibitors of NE have been developed
and trialed. NE was chosen as a target for inhibition by
synthetic compounds due to its being widely recognized
as the key serine protease connected to lung pathology in
CF. DX-890 is a small protein inhibitor of NE, which has
been shown to be tolerable in rat and in humans after a
phase I clinical trial [116, 117]. This compound was shown to
inhibit NE released from both healthy and CF neutrophils
when treated at concentrations above 100 nM [118]. DX-
890 also reduced IL-8 release from both healthy and CF
neutrophils and reduced neutrophil transmigration through
the epithelial barrier [118]. A second trial using DX-890 as
a NE inhibitor in CF showed it to be only partially effective
at inhibiting NE in CF sputum; however this study only
tested DX-890 against low molecular ratios of NE, which
do not adequately represent the levels observed in the CF
lung [119]. Another compound trialled is AZD9668, an orally
administered reversible inhibitor of NE [120]. A phase II
clinical trial looking at its efficacy in bronchiectasis showed
reductions in proinflammatory cytokines IL-6 and IL-8 and
improvements in FEV
1
; however sputum neutrophils were
not shown to be decreased [121, 122]. A trial looking at
AZD9668use as aCF therapeutic showed similar results, with
reports of a reduction in pro-inflammatory cytokines which
was postulated to be due to inhibition of elastin cleavage by
NE [123].
4. Conclusion
An increasing volume of experimental evidence points to
the importance of proteases and their cognate protease
inhibitors in CF lung disease. The imbalance of the pro-
tease/antiprotease balance in favor of the neutrophil serine
proteases results in a self-perpetuating cycle of inflammation
and respiratory tissue damage. This evidence also points
to therapeutic options for the treatment of CF patients
to reduce the inflammatory tissue damage in the form of
antiprotease therapy using either synthetic antiproteases or
mutated endogenous antiproteases. Clinical trials have shown
that the application of antiproteases such as SLPI and AAT
results in the reduction of inflammation due to the restora-
tion of the protease/antiprotease balance. The therapeutic
and diagnostic applications of research into proteases and
antiproteases in the CF lung continue to attract significant
interest.
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